507
Participants
Start Date
March 31, 2016
Primary Completion Date
July 21, 2017
Study Completion Date
March 13, 2018
Ovaleap®
"About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births)."
Teva Investigational Site 034, Aalen
Teva Investigational Site 033, Kempten (Allgäu)
Teva Investigational Site 026, München
Teva Investigational Site 032, Regensburg
Teva Investigational Site 035, Ludwigshafen am Rhein
Teva Investigational Site 036, Aalen
Teva Investigational Site 004, Berlin
Teva Investigational Site 015, Berlin
Teva Investigational Site 017, Berlin
Teva Investigational Site 027, Berlin
Teva Investigational Site 031, Berlin
Teva Investigational Site 022, Bielefeld
Teva Investigational Site 013, Dortmund
Teva Investigational Site 003, Düsseldorf
Teva Investigational Site 010, Düsseldorf
Teva Investigational Site 011, Essen
Teva Investigational Site 025, Esslingen am Neckar
Teva Investigational Site 012, Großhansdorf
Teva Investigational Site 037, Hamburg
Teva Investigational Site 016, Hanover
Teva Investigational Site 028, Hildesheim
Teva Investigational Site 021, Kiel
Teva Investigational Site 029, Leipzig
Teva Investigational Site 014, Ludwigsburg
Teva Investigational Site 020, Lübeck
Teva Investigational Site 023, Magdeburg
Teva Investigational Site 006, München
Teva Investigational Site 030, München
Teva Investigational Site 018, Münster
Teva Investigational Site 009, Osnabrück
Teva Investigational Site 007, Regensburg
Teva Investigational Site 002, Rostock
Teva Investigational Site 008, Saarbrücken
Teva Investigational Site 019, Stuttgart
Teva Investigational Site 005, Ulm
Teva Investigational Site 024, Ulm
Teva Investigational Site 001, Wiesbaden
Teva Pharma GmbH
INDUSTRY